Expression Of Dendritic Cells And T-lymphocytes In Epithelial Ovarian Cancer Correlates With Clinical Significance

Objective:Ovarian malignancy is one of the three malignant tumors ofthe female genital tract common, but the mortality rate is the first. Ovariancancer has variable tissue types and epithelial ovarian cancer is the mostcommon. EOC can’t be found easily in early and about70%patients beenfound is so late,the EOC patients are very sensitive to the initial surgery andchemotherapy, but the effect is not obviously, the5-year survival rate ishovering in the30%to40%.The tumor prognosis depends on many factors, including the stage andgrade of the tumor, the expression of oncogenes, vascular invasion.Theexpression of dendritic cells probably becomes another factor which caninfluence the tumor prognosis.Dendritic cell is widely distributed in lymphoidand non-lymphoid tissues and it is APC with powerful function,who canactivate native T cells. DC can capture, process and present the antigen, andexpression of MHC-II molecules and costimulatory molecules in the antigencommission process.DC activates T cells depends on two activation signal(peptide-MHC-TCR complex and costimulatory molecules CD80/86combined with CD28molecules,which is expressed by CD4+Tlymphocyte).Through stimulating special CTL and helper cell (Th)proliferation, DC can achieve the purpose of the anti-tumor by stimulatingtumor immunity or enhancing the immune response.At present, we can findthe relationship between prognosis with DC infiltration in some tumors,including melanoma, head and neck cancer, tongue cancer, cervical cancer.To explore the relationship between the distribution and expression ofDC cell surface molecules, such as HLA-DR, S-100, CD1a, CD80and CD86and lymphocytes CD45RA, CD45RO in epithelial ovarian cancer withclinicopathological parameters and prognosis of ovarian cancer.Analyze the correlation between DC and EOC.Methods:The clinicopathologic factors and outcomes of33patients withepithelial ovarian cancer,who underwent surgical treatment and confirmed bypathology, from Jan,1999to Dec,1999in the Fourth Hospital of HebeiMedical University,were reviewed and analyzed.All cases were follow-upvisited and the follow-up deadline was Dec,2009.32patients completed andthe rate of follow-up was96.97%. Analyze the correlation between the DCmarkers with clinicopathological parameters and prognosis of ovarian cancer.The data Statistical Analysis were performed using SPSS16.0statisticalsoftware. Ranked data using the Wilcoxon rank test or K-Wtest.Kaplan-Meier method was used to calculate survival rates.Spearmanrank correlation was uesd for analyzing correlation.Evaluated the prognosticfactors by univariate and multivariate analysis. Univariate analysis and thecomparison between the survival rates was estimated by Log-ranktest.Multiple regression analysis of survival time were assessed by Coxproportional hazards model.A statistically significant difference was indicatedby P <0.05.Results:1There was difference of CD45RA positive rate between50.9%in earlyovarian cancer and10.5%in advanced ovarian cancer.There were nosignificant difference in surgical-pathological staging for HLA-DR, S-100,CD1a, CD80and CD86, CD45RO.2There were no significant difference of positive rate in pathologicaltype and histological grade for HLA-DR, S-100, CD1a, CD80and CD86,CD45RO,CD45RA.3Univariate analysis revealed that CD45RO,histologicalgrade,surgical-pathological stage were significantly associated with overallsurvival.4There was significant difference of the co-expression of CD1a+DC/CD45RO+T lymphocyte and S-100+DC/CD45RO+T lymphocyte with cumsurvival. 5There was positive correlation between the co-expression of CD45RA/CD45RO with pathological stage.6Multivariate analysis revealed that histologicalgrade,surgical-pathological stage were independent prognostic factorsassociated with overall survival.There was significant difference ofsurgical-pathological stage(P<0.05,r=-0.535) and histologicalgrade(P<0.05,r=-0.794) with cum survival.7The3-year,5-year,10-year overall survival rates were42.4%,22.8%,6.5%in ovarian carcinoma. The median survival time is33months.Conclusion:1The co-expression of DC with CD45RO+T lymphocytes can be thoughtto reflect the interaction between the host immune system and tumor cells.2Histological grade and surgical-pathological stage were the independentprognostic factors associated with overall survival.